Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase

Article

Abstract: Background: Cushing's disease is a rare endocrine disorder characterised by cortisol overproduction

Palabras claves:

Autores:

Bertagna X., Biller B.M.K., Findling J.W., Fleseriu M., Gu F., Kim J.H., Lacroix A., Laplanche A., Lee E.J., Leelawattana R., Newell-Price J., O'Connell P., Pedroncelli A.M., Pivonello R., Richard J. Auchus, Shimatsu A., Tauchmanova L.

Fuentes:

scopus